Leeds, UK -- (SBWire) -- 07/09/2019 --Global Immune repertoire sequencing market is forecasted to value over US$ 175 Million by 2029 end and register a CAGR of over 7.5% from 2019 to 2029.
Immune repertoire sequencing is vastly utilized in biomarker discovery. It's used to improve the cost-effectiveness and success rate of drug development. Immune repertoire sequencing is significant in understanding the human body's auto-defence technique against external agents.
Increasing research and development have been stimulating the growth of the market. According to FutureWise's recent research, immune repertoire sequencing can be used to detect systemic sclerosis-related pulmonary hypertension (SSc-PAH). Hence, increasing research is fueling the growth of the market. Rising prevalence of cancer and other infectious diseases is also boosting the growth of the market. Prominent players launching innovative products is further boosting the growth of the market. The innovation of products has led to extensive use of clinical requirements for patients which are fueling the growth of the market.
The immune repertoire sequencing market is segmented by component, by application, and by the end user. By component, the market is bifurcated into assay kits and software & services. The assay kits are further divided into TCR Kits and BCR Kits. Assay kit is expected to hold a major share of the market in the forecast period.
TCR Kits control the adaptive immune system's capability to create a vast collection of T-cell receptors. Multiple companies are looking for mergers in order to develop repertoire sequencing kits for immunotherapy response of a specific kind. For example, MIODx and DiaCarta collaborated together to develop MIODX's ClonoMapto predict the response of the patient to immunotherapy. Such kits will help in providing an accurate understanding of response and behaviour of adaptive immunity.
On the basis of software & services, the market is bifurcated into analytical software, sequencing services, and data analysis services.
The end users of the market are infectious diseases, vaccine development, cancer immunotherapy, autoimmune disease, and transplant rejection & tolerance. Rising infectious diseases and research regarding cancer immunotherapy is expected to drive the growth of the market.
The challenges concerning distinguishing biological variations from errors are expected to hinder the growth of the market. Limitation in providing accurate data has resulted in unsatisfactory performance from bioinformatics techniques like high throughput screening which has placed further restrains regarding the growth of the market.

Request a Sample Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=256&page=requestsample

The challenges concerning distinguishing biological variations from errors are expected to hinder the growth of the market. Limitation in providing accurate data has resulted in unsatisfactory performance from bioinformatics techniques like high throughput screening which has placed further restrains regarding the growth of the market.
In terms of region, North America is expected to hold a vast share of the market. Rising demand for immunotherapy for other infectious diseases and cancer is the key reason behind the growth of the market in the region. According to the U.S National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. Immune repertoire sequencing plays a vital role in fighting cancer and other infectious diseases.
Europe is expected to achieve the highest growth during the forecast period. Increased funding by the government alongside rising healthcare expenditure is expected to expand the size of the market in the region. Asia-Pacific region is also predicted to exhibit immense market growth in the coming years. Accelerating adoption of immune repertoire sequencing in developing nations is expected to spur the size of the market. Latest developments by developing countries like Japan for the integration of advanced technology are expected to stimulate the size of the market.
Prominent players of the market are CD Genomics, Atreca Inc., ArcherDX, Illumina Inc., Roche Holding AG, Adaptive Biotechnologies and ThermoFisher Scientific Inc.
Global Immune Repertoire Sequencing Market Segmentation:
By Component
Assay Kits
- TCR Kits
- BCR Kits
Software & Services
- Analytical Software
- Sequencing Services
- Data Analysis Services

Purchase a Copy of this Premium Research Report At: https://www.futurewiseresearch.com/pressrelease/Global-Immune-Repertoire/192

By Application
- Biomaker Discovery
- Infectious Diseases
- Vaccine development and efficacy
- Cancer Immunotherapy
- Autoimmune Disease
- Transplant rejection and Tolerance
- Others

By Region:
- Europe
- North America
- APAC
- Latin America
- Rest of World

Competitive Landscape:
- Tier 1 players- established companies in the market with a major market share
- Tier 2 players
- Emerging players which are growing rapidly
- New Entrants

FutureWise Takeaways:
- Growth prospects
- SWOT analysis
- Key trends
- Key data points affecting market growth

Objectives of the Study:
- To provide with an exhaustive analysis on the immune repertoire sequencing market based on the components, end users and region
- To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
- To evaluate and forecast micro-markets and the overall market
- To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
- To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
- Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Inquire further details about this report at: sales@futurewiseresearch.com

About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.

Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: sales@futurewiseresearch.com
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com